Belzutifan Active in Renal Cell Carcinoma Associated With VHL Disease
Objective response seen in 49 percent of patients with renal cell carcinoma associated with von Hippel-Lindau disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.